Beta-2 Polymorphisms and Beta Receptor Selectivity

The Effects of ß2 Polymorphisms on Beta Selectivity After ß-adrenergic Blockade in Patients With Heart Failure

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00214318

Enrollment

Registered

2005-09-21

Start date

2005-01-31

Completion date

2007-02-28

Last updated

2015-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

We hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients with heart failure treated with either a b1-selective or a b-nonselective agent. b-2 polymorphisms may contribute to differing responses to drug treatment with beta-blockers in heart failure. Characterizing these polymorphisms may help explain the variability in the degree of selectivity of action of b-blockers at the b receptor, namely if their action is specific for the b-1 or b-2 receptor. Part A was conducted at the University of Utah, and all subjects completed study related activities. Part B (sub-study) consists of genotyping of blood samples collected in part A, which will be completed at the University of Wisconsin. Sub-study (samples and DNA isolation) or Part B entailed analyzing an extra 10 mL of blood that was taken for DNA isolation. Genotyping (i.e. determination of genetic makeup) of beta adrenergic polymorphisms utilized polymerase chain reaction followed by pyrosequencing.

Interventions

DRUGTerbutaline plus Metoprolol or carvedilol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* systolic dysfunction with ejection fraction ≤40% * symptomatic heart failure class 2-3 * \>18 years of age * optimal medical therapy of HF excluding the use of any beta-blockers within the previous 30 days of the study

Exclusion criteria

* active myocarditis * hemodynamically significant valvular heart disease * hypertrophic cardiomyopathy * contra-indications to beta-blockers * concomitant use of beta-agonists * beta-antagonist or anti-arrhythmics * unstable angina * myocardial infarction or bypass surgery within 3 months * significant renal insufficiency \[creatinine \>2.5 mg/dL\], liver disease, or anemia

Design outcomes

Primary

Measure	Time frame
The effect of beta-2 polymorphisms on potassium changes in response to terbutaline infusions	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026